Folder 01
Part IV · The Four Interaction Cascades
- The operational record is sound.
- Risk concentrates in four interactions, not in any single ingredient.
- Read this matrix before changing any dose.
| # | Cascade | Components and summed dose | Mechanism | Practical consequence |
|---|---|---|---|---|
| 1 | Piperine drug- |
TESTOFX BioPerine 9.5 mg + Curcumin BioPerine 5 mg = 14.5 mg/day (training days) | Inhibits intestinal P-glycoprotein and hepatic CYP3A4 plus phase-II glucuronidation | Raises systemic exposure to co-administered drugs and to the stack itself. Disclose to prescribers. |
| 2 | ALA to insulin autoimmune syndrome | R-ALA 300 mg + glycogen- |
Health Canada flags alpha-lipoic acid for IAS (Hirata disease) in HLA-DRB1*0406 / *0403 carriers | Hypoglycaemia symptoms post- |
| 3 | Osmotic GI stack without a gallbladder | Magnesium 341-646 mg + high- |
Osmotic water draw compounds bile-related stool looseness | Loose stools are predictable system output; log and moderate fat bolus before blaming single foods. |
| 4 | Stimulant stack at the ceiling | IGNITER about 373 mg caffeine + TeaCrine (theacrine half-life 16-20 h) + Dynamine + theobromine + Earl Grey 40-70 mg | Overlapping methylxanthine exposure across the day | Exposure regularly crosses the 400 mg/day guidance; sleep is the limiting organ. |